Navigation Links
Saw palmetto no more effective than placebo for urinary symptoms
Date:9/27/2011

Saw palmetto, a widely used herbal dietary supplement, does not reduce urinary problems associated with prostate enlargement any better than a placebo, according to research funded by the National Institutes of Health. The study was published Sept. 28 in the Journal of the American Medical Association.

Prostate enlargement, also called benign prostatic hyperplasia (BPH), can cause frequent urination, a weak or intermittent urine stream and an inability to empty the bladder completely. More than half of men in their 60s, and up to 90 percent in their 70s and 80s, have symptoms of BPH.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Center for Complementary and Alternative Medicine (NCCAM) and the Office of Dietary Supplements (ODS) supported the study. All are part of the NIH.

According to Robert A. Star, M.D., director of the NIDDK's Division of Kidney, Urologic and Hematologic Diseases, the current study met an important need for rigorous evaluation of standard and higher doses of saw palmetto. The trial also confirmed results of the earlier NIDDK- and NCCAM-sponsored Saw Palmetto Trial for Enlarged Prostates (STEP), which found that a standard daily dose of 320 milligrams provided no greater symptom relief than placebo.

"Investigators designed the current trial to determine whether daily doses of up to 960 milligrams three times the standard daily dose -- would prove better than a placebo at improving lower urinary tract symptoms in men due to BPH," said Star. "We were disappointed to find that higher doses of saw palmetto did not improve symptoms more than placebo."

Josephine P. Briggs, M.D., director of NCCAM, added that this study further illustrates the importance of conducting research on botanical products that are used extensively by the general public.

"This was a well-designed study that addressed limitations of earlier, smaller trials it was a multicenter study with a larger sample size and tested different doses of a carefully analyzed saw palmetto product," Briggs said. "The NIH is committed to bringing rigorous science to the study of natural products and to building the evidence base that can guide consumer decisions."

The study was a double-blind randomized placebo-controlled clinical trial conducted at 11 North American clinical sites from June 2008 to October 2010. A cohort of 369 men aged 45 years or older participated, each with a peak urine flow rate of at least four milliliters per second at the beginning of the study -- which is less than normal. Also, all had an American Urological Association Symptom Index (AUASI) score of between eight and 24 -- a lower score is better. The AUASI score ranges from zero to 35. Escalating doses of saw palmetto or placebo were given, starting at one, then two, and then three pills of 320 milligrams per day, with dose increases at 24 and 48 weeks.

The study measured the differences between the AUASI score at the start of the trial and after 72 weeks of treatment. Secondary measures included improvements in frequency, nocturia (nighttime urination), peak urine flow, prostate-specific antigen (PSA) level, sexual function, incontinence and sleep quality.

Between baseline and 72 weeks, mean AUASI scores decreased from 14.4 to 12.2 points with saw palmetto extract and from 14.7 to 11.7 points with placebo. The group average change in AUASI score from baseline to 72 weeks between the saw palmetto and placebo groups was 0.79 points, favoring placebo. Saw palmetto was not more effective than placebo in reducing urinary symptoms for any of the secondary outcomes.

According to Joseph M. Betz, Ph.D., director of the Analytical Methods and Reference Materials program at ODS and a study co-author, the study used a very well-characterized saw palmetto product. Through batch testing, study investigators took extreme care to ensure that the composition of the supplement was consistent over the whole study.

"Saw palmetto and other herbs are often manufactured in different ways, so no two brands are likely to have the same composition," Betz said.

Rottapharm/Madaus, Cologne, Germany, donated the saw palmetto extract and matching placebo used in the study.


'/>"/>

Contact: Bill Polglase
NIDDKMedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Related medicine news :

1. Palmetto Insurance Provides Individual Health Insurance In both North and South Carolina
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Gastric Banding Most Effective for Obese Teens
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. Charging less for more effective treatments could reduce health care costs while improving health
7. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
8. New drug for kidney transplant recipients effective in humans
9. Two Sepsis Treatments Look Equally Effective
10. Mammogram Plus MRI Seems Cost-Effective in High-Risk Women
11. Mammogram Plus MRI Cost-Effective in High-Risk Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Farmingdale, NY (PRWEB) , ... March 27, 2017 ... ... specializing in epigenetic research products enables researchers to pursue the recent RNA methylation ... RNA methylation . In light of the newfound characteristics of N6-methyladenosine, or ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare ... will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will ... chain and value analysis professionals have a ‘seat at the table’ with clinical ...
(Date:3/27/2017)... ... ... According to the American Cancer Society , the average 15-year survival ... the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year survival ... latter group, tune in to Lifestyle Magazine on April 9, 2017, to ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... agreement to resolve the pending litigation between itself and 1800 Vending DBA Healthy ... Utah). , “I am thrilled to announce that we have now reached a ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
Breaking Medicine Technology: